{"podcast":{"title":"Hims House","slug":"hims-house-7026583","podcast_index_feed_id":7026583,"rss_url":"https://anchor.fm/s/10e9c0874/podcast/rss","website_url":"https://himshouse.substack.com/podcast","image_url":"https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/45300741/1466fea8bed61dc7.jpg","author":"Jonathan Stern","episode_count":73,"summary":"Hims House is the ultimate podcast for Hims & Hers investors. Hosted by Jonathan Stern and Patrick Lester, Hims House breaks down all the key questions shaping $HIMS — from telehealth and pharma to GLP-1s, compounding, and the future of healthcare. New episodes every week. himshouse.substack.com","last_synced_at":"2026-07-08T00:20:15.279819+00:00","page_url":"https://stenobird.com/podcast/hims-house-7026583"},"episode":{"title":"Shalin Shah - CEO of Marius Pharmaceuticals on the oral TRT partnership with Hims","slug":"shalin-shah-ceo-of-marius-pharmaceuticals-on-the-oral-trt-partnership-with-hims","published_at":"2025-11-10T14:27:55+00:00","page_url":"https://stenobird.com/podcast/hims-house-7026583/shalin-shah-ceo-of-marius-pharmaceuticals-on-the-oral-trt-partnership-with-hims","show_page_url":"https://stenobird.com/podcast/hims-house-7026583","url":"https://podcasters.spotify.com/pod/show/jonathan-stern1/episodes/Shalin-Shah---CEO-of-Marius-Pharmaceuticals-on-the-oral-TRT-partnership-with-Hims-e3egqke","audio_url":"https://anchor.fm/s/10e9c0874/podcast/play/114894926/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-2%2F417288005-44100-2-8a5bf478189186cd.mp3","summary":"Shalin Shah is the founder & CEO of Marius Pharmaceuticals, the company that partnered with $HIMS to launch oral testosterone (KYZATREX). We discuss how the partnership came about, the benefits of teaming up with $HIMS, and the future of TRT. (00:41) Origin of the partnership (02:55) Benefits of partnering with $HIMS (04:14) Deal shape and exclusivity (06:51) How KYZATREX will sit alongside compounded meds on the $HIMS platform (09:22) Will KYZATREX be personalized? (16:07) TRT as a schedule 3 substance (21:39) Gearing up for 2026 launch of KYZATREX (22:40) Future of TRT market (27:29) Peptides (29:44) Testosterone for females Get full access to Hims House at himshouse.substack.com/subscribe","meta_description":"Shalin Shah is the founder & CEO of Marius Pharmaceuticals, the company that partnered with $HIMS to launch oral testosterone (KYZATREX). We discuss h…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1955,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/shalin-shah-ceo-of-marius-pharmaceuticals-on-the-oral-trt-partnership-with-hims/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/hims-house-7026583/shalin-shah-ceo-of-marius-pharmaceuticals-on-the-oral-trt-partnership-with-hims.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}